LEADER 03991nam 22006255 450 001 9911018657103321 005 20250808191817.0 010 $a9783031938948$b(electronic bk.) 010 $z9783031938931 024 7 $a10.1007/978-3-031-93894-8 035 $a(MiAaPQ)EBC32246535 035 $a(Au-PeEL)EBL32246535 035 $a(CKB)39723005200041 035 $a(DE-He213)978-3-031-93894-8 035 $a(EXLCZ)9939723005200041 100 $a20250726d2025 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aReceptor Tyrosine Kinases in Cancer /$fedited by Akash Sabarwal, Saba Tabasum, Soumitro Pal 205 $a1st ed. 2025. 210 1$aCham :$cSpringer Nature Switzerland :$cImprint: Springer,$d2025. 215 $a1 online resource (575 pages) 225 1 $aCancer Drug Discovery and Development,$x2196-9914 311 08$aPrint version: Sabarwal, Akash Receptor Tyrosine Kinases in Cancer Cham : Springer,c2025 9783031938931 327 $aAn Introduction to Receptor Tyrosine Kinases Signal Transduction and Cancer Progression -- Tyrosine Kinases and Inflammatory Signaling in Cancer -- Molecular Mechanisms of Acquired Therapeutic Resistance to Tyrosine Kinase Targeted Therapy -- AXL and its Role in Cell Migration and Epithelial to Mesenchymal Transition -- VEGFR and its Role in Tumor Angiogenesis -- c-MET Therapeutic Target and Biomarker in Cancer -- Receptor Tyrosine Kinase signaling and Mitochondria -- Therapeutic Potential of Targeting Immune Checkpoints Along with RTKs -- Combination therapies involving RTK inhibitors -- RTKs as a Therapeutic Target by Natural Compounds in Cancer Treatment. 330 $aReceptor tyrosine kinases (RTKs) play a critical role in a variety of cellular processes including growth, differentiation, motility, and metabolism. RTKs are frequently overexpressed and their aberrant signalling is associated with various diseases including cancer. Thus, RTKs have become one of the most important druggable targets for the treatment of cancer. The emergence of small kinase inhibitors in cancer treatment offers a strategic approach to the management of cancer that surpasses the efficacy of traditional drugs. Understanding RTK signaling mechanisms is of paramount importance, especially as the US FDA and other global regulatory agencies have approved several small-molecule tyrosine inhibitors. Moreover, pharmaceutical companies are actively developing new compounds for the treatment of various malignancies. This comprehensive book addresses a timely need by presenting the latest advances and cutting-edge insights into RTKs in cancer research. The chapters provide overviews and recent developments regarding the roles of key RTKs ?such as, c-Met, AXL, VEGFR, EGFR, among others?in pro-tumorigenic signaling, therapeutic resistance, and targeted inhibition across different cancer types. This volume serves as an essential resource for researchers and students seeking to deepen their understanding of this rapidly evolving field. . 410 0$aCancer Drug Discovery and Development,$x2196-9914 606 $aCancer 606 $aMolecular biology 606 $aBiophysics 606 $aCell interaction 606 $aCancer Biology 606 $aMolecular Biology 606 $aMechanobiological Cell Signaling 615 0$aCancer. 615 0$aMolecular biology. 615 0$aBiophysics. 615 0$aCell interaction. 615 14$aCancer Biology. 615 24$aMolecular Biology. 615 24$aMechanobiological Cell Signaling. 676 $a571.978 676 $a616.994 700 $aSabarwal$b Akash$01836963 701 $aTabasum$b Saba$01836964 701 $aPal$b Soumitro$01836965 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 912 $a9911018657103321 996 $aReceptor Tyrosine Kinases in Cancer$94415190 997 $aUNINA